Photodynamic diagnosis by using 5-aminolevulinic acid in pancreaticobiliary neoplasm

Photodynamic diagnosis by using 5-aminolevulinic acid in pancreaticobiliary neoplasm - Diagnosis using 5-aminolevulinic acid in pancreaticobiliary neoplasm

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000016702

Enrollment

100

Registered

2015-03-05

Start date

2013-07-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreaticobiliary tumor

Interventions

A single oral administration of 5-aminolevulinic acid (1g)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients who have an abnormality of biliary tree and/or pancreas. 2. Patients who provide a written informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with porphyria. 2. Patients with hypersensitivity to 5-aminolevulinic acid or porphyrins. 3. In cases of known or suspected pregnancy or woman who are breast-feeding. 4. Patients who doctors regard as inappropriate ones for the enrollment due to some reasons.

Design outcomes

Primary

Measure	Time frame
Diagnostic accuracy of 5-aminolevulinic acid in pancreaticobiliary neoplasm	—

Countries

Japan

Contacts

Public ContactTsukasa Ikeura

Kansai Medical University The Third Department of Internal Medicine

ikeurat@hirakata.kmu.ac.jp072-804-0101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026